Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis

New England Journal of Medicine

Volumn 339, Issue 9, 1998, Pages 578-583

  Kaufman, James S ^a,g   Reda, Domenic J ^b   Fye, Carol L ^c   Goldfarb, David S ^d   Henderson, William G ^b   Kleinman, Jack G ^e   Vaamonde, Carlos A ^f  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hines VA Coop Studs Prog C   (United States)

^c Vet Aff Coop Studs Prog C   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIALYSIS; FEMALE; HEMODIALYSIS; HUMAN; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ALGORITHMS; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; FEMALE; HEMATINICS; HEMATOCRIT; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PAIN; RENAL DIALYSIS;

EID: 0032572918     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808273390902     Document Type: Article

References (31)

1. Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int 1996;50:1373-91.
2. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
3. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ 1989;299:157-8.
4. Rao DS, Shih M, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-5.
5. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996;334:420-5.
6. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990;29:709-13.
7. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76:1718-22.
8. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer H-H. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 1992; 34:499-508.
9. Frenken L, van Lier HJ, Gerlag PG, den Hartog M, Koene RA. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving hemodialysis. BMJ 1991;303:288.
10. Granolleras C, Leskopf W, Shaldon S, Fourcade J. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. Clin Nephrol 1991;36:294-8.
11. Woolson RF. Statistical methods for the analysis of biomedical data. New York: John Wiley, 1987.
12. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992;2:1405-16.
13. Zehnder C, Blumberg A. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration. Nephron 1991;57:485-6.
14. Schaller R, Sperschneider H, Thieler H, et al. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial. Artif Organs 1994;18:552-8.
15. Eidemak I, Friedberg MO, Ladefoged SD, Lokkegaard H, Pedersen E, Skielboe M. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Nephrol Dial Transplant 1992;7:526-9.
16. Paganini EP, Eschbach JW, Lazarus JM, et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis 1995;26:331-40.
17. Parker KP, Mitch WE, Stivelman JC, Macon EJ, Bailey JL, Sands JM. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 1997;8:288-93.
18. Albitar S, Meulders Q, Hammond H, Soutif C, Bouvier P, Pollini J. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 1995;10:Suppl 6:40-3.
19. Tomson CR, Feehally J, Walls J. Crossover comparison of intravenous and subcutaneous erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1992;7:129-32.
20. Steffensen G, Aunsholt NA, Ahlbom G. Comparative crossover study of intravenously and subcutaneously administered recombinant human erythropoietin in hemodialysis patients. Blood Purif 1992;10:241-7.
21. Virot JS, Janin G, Guillaumie J, et al. Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient? Am J Kidney Dis 1996;28:400-8.
22. Muirhead N, Churchill DN, Goldstein M, et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 1992;12:303-10.
23. Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clin Nephrol 1994;41:297-302.
24. Canaud B, Bennhold I, Delons S, et al. What is the optimum frequency of administration of r-HuEPO for correcting anemia in hemodialysis patients? Dial Transplant 1995;24:306-29.
25. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients: IV and SC erythropoietin. Eur J Clin Pharmacol 1996;50:171-7.
26. Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991;59:399-402.
27. Barclay PG, Fischer ER, Harris DC. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin. Clin Nephrol 1993;40:277-80.
28. Kooistra M, van Es A, Struyvenberg A, Marx JJ. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 1991;79:634-9.
29. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30:Suppl 3:S192-S240.
30. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-12.
31. Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol 1992; 12:68-72.